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Remacemide hydrochloride is a low-affinity, non-competitive N -methyl-D-aspartic acid (NMDA) receptor channel blocker,
under investigation in epilepsy. This double-blind, placebo-controlled, multicentre study assessed the safety and efficacy of
remacemide hydrochloride or placebo, as adjunctive therapy, in 252 adult patients with refractory epilepsy who were already
taking up to three antiepileptic drugs (including an enzyme-inducer). Patients were randomized to one of three doses of
remacemide hydrochloride (300, 600 or 1200 mg/day) or placebo Q.I.D., for up to 15 weeks. An increasing percentage
of responders (defined as a reduction in seizure frequency from baseline of ≥50%) was seen with increasing remacemide
hydrochloride dose. At 1200 mg/day, 23% of patients were responders compared with 7% on placebo. This difference was
significant (P = 0.016), as was the overall difference between treatments (P = 0.038). Adverse events: dizziness, abnor-
mal gait, gastrointestinal disturbance, somnolence, diplopia and fatigue were mild or moderate in severity. Carbamazepine
and phenytoin plasma concentrations were well controlled and maintained within target ranges, with no evidence of im-
proved seizure control due to increases in the concentrations of these drugs. A dose-dependent, significant, increase in respon-
ders following adjunctive remacemide hydrochloride compared with placebo was observed. Remacemide hydrochloride was
well tolerated.
c© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved
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INTRODUCTION
Remacemide hydrochloride is a new antiepileptic
drug (AED) with a novel mechanism of action.
Remacemide and its principal active desglycinyl
metabolite, are low affinity, non-competitive N -
methyl-D-aspartic acid (NMDA) receptor channel
blocking agents with additional significant sodium fast
channel blocking activity1. This study was designed
to establish an active dose range for remacemide
hydrochloride, in a Q.I.D. regimen, as adjunctive
therapy in refractory patients with epilepsy receiving
hepatic enzyme inducing AEDs. Early studies have
shown that plasma concentrations of remacemide
and the desglycinyl metabolite are reduced in the
presence of hepatic enzyme-inducing drugs such as
carbamazepine (CBZ) and phenytoin (PHT)2, 3. In
turn, interaction studies have shown that remacemide
increases plasma concentrations of CBZ3 and PHT4
by inhibiting their metabolism. Plasma concentrations
of CBZ and PHT were maintained within pre-
determined limits by adjusting the dose of these drugs,
as necessary, on an individual patient basis.
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MATERIALS AND METHODS
The study was approved by the appropriate ethics
committee at each centre. All patients gave informed
consent before study entry and the study was
conducted in accordance with the Declaration of
Helsinki. Patients were recruited at 23 centres in the
UK, Denmark, Holland and Sweden. The first patient
entered the study in April 1993 and the last patient
completed in September 1995.
Study population
Adult patients aged 18–70 years, with a documented
history of partial seizures with or without secondary
generalization or primary tonic–clonic seizures, taking
up to three AEDs, including at least one hepatic
enzyme-inducing drug (CBZ, PHT, phenobarbital
or primidone), were enrolled. To enter the double-
blind phase, patients had to have an average seizure
frequency of at least four seizures per month during
baseline. Patients were excluded if they had other sig-
nificant medical history or a history of pseudoseizures.
Women of child-bearing potential were excluded
unless, in the opinion of the investigator, they were
reliable users of an effective contraceptive method.
A total of 240 patients were planned to complete the
study (60 in each of four treatment groups). Assuming
that 10% of patients in the placebo group would
respond to treatment (response to treatment defined as
a 50% or greater reduction in seizure frequency when
compared with baseline), this sample size allowed
the detection of a true difference of 23% or greater
between the active treatment groups and placebo,
based on two-tailed statistical tests with a 5% level of
significance and 80% power.
Study design
The study design is shown in Fig. 1.
On entry into the run-in period, the total daily
dose of CBZ administered was the patient’s usual
dose given in either a T.I.D. or Q.I.D. regimen. The
daily dose was given as regular Tegretolr tablets
(Novartis Pharmaceuticals) and one or two blinded
capsules containing Tegretolr tablets. During the
run-in period the patient’s daily dose of CBZ was
adjusted on a weekly basis, if necessary, until the
investigator had established that the patient was stable
on a particular dose.
After completing the run-in period, patients entered
a 2-month baseline period and were assessed at 2-
weekly intervals and provided blood samples for
measurement of CBZ or PHT. These results were used
in conjunction with a Shewhart control chart5 to define
a ‘target range’ for CBZ or PHT concentration for each
patient. During the baseline period, patients continued
to take the dose of CBZ on which they were stabilized.
Patients not taking CBZ entered baseline directly.
After the baseline period, patients who continued
to fulfil the entry criteria were randomized to
placebo or remacemide hydrochloride (300, 600 or
1200 mg/day), in a Q.I.D. regimen, for 15 weeks.
For the groups allocated the 600 mg/day and
1200 mg/day treatments, the dose of remacemide
hydrochloride was gradually increased during the dose
titration phase (7 weeks) of the double-blind treatment
period. Patients then continued to receive the allocated
dose for a further 8 weeks (continuation phase of
the double-blind treatment period). Patients recorded
adverse events, seizure type, frequency and severity
on diary cards. Efficacy was assessed by comparing
seizure frequency during the continuation phase with
that during baseline.
During the double-blind period, an unblinded
observer monitored plasma CBZ concentrations and
instructed the pharmacist to vary, when necessary, the
dosage strength of CBZ in the blinded capsules to
maintain the plasma concentrations of CBZ within the
established ‘target range’. Neither the investigator nor
the patient was aware what dose had been given in
the capsules.
If a dose change was required, the pharmacist
exchanged a bottle of CBZ capsules with the patient,
within 2 days after a clinic visit, using a courier.
During the continuation phase, a number of courier
visits were made at random to maintain the blind;
these patients were given a dose of CBZ identical
to that which they were already receiving. PHT
was not blinded because although remacemide may
increase plasma PHT concentrations, in some patients
increases also occur at random on placebo. For
patients taking PHT, the investigators reviewed the
plasma concentrations and adjusted the dose at
their discretion.
At the end of the double-blind period, patients
chose either to discontinue treatment or to enter
an open-label extension study. For patients who
chose to withdraw, study treatment was withdrawn
gradually over 12 days to reduce the theoretical
risk of rebound seizure activity. Patients who chose
to continue treatment entered a 4-week double-
blind transition period, during which the dose of
remacemide hydrochloride was adjusted gradually so
that all patients entered the extension study on a dose
of 800 mg/day.
Each day throughout the study, patients recorded
adverse events, seizure type and frequency on a diary
card. At each clinic visit, safety was assessed by clini-
cal examination, electrocardiogram (ECG) and routine
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Fig. 1: Study design.
laboratory tests. Blood samples were taken at the end
of the baseline period and throughout the double-blind
period for measurements of plasma concentrations
of remacemide and its desglycinyl metabolite. Blood
samples were taken for measurement of other AEDs,
as appropriate.
Outcome measures
The primary outcome measure was the percentage
of patients who responded to treatment, i.e. who
had a 50% or greater reduction in monthly seizure
frequency compared with baseline. An additional
efficacy measure was the median percentage reduction
in monthly seizure frequency.
The safety variables were adverse events, haema-
tology and biochemistry, urinalysis, ECGs and
vital signs.
Statistical analysis
The null hypothesis was that placebo and remacemide
were equivalent. The analysis plan specified that the
efficacy analyses would be based on all patients
who completed at least 14 days of study treatment
following the titration period. The number of respon-
ders (i.e. ≥50% reduction in seizure frequency) was
compared using a chi-square test. Where treatment
effects were seen, pairwise comparisons between
groups were carried out, also using a chi-squared
test. The Kruskal–Wallis statistical test6 was used
to compare seizure frequency between treatments.
All randomized patients were included in the safety
analyses. Analysis of variance was used to compare
treatment groups for laboratory variables, ECG
parameters and vital signs.
An adjustment was made for centre in most
analyses. Data from each time point was analysed
separately using analysis of variance with treatment,
centre and treatment-by-centre interactions as factors.
No adjustment was made for multiple testing.
RESULTS
Patient characteristics
All patients were Caucasian and the four treatment
groups were similar with respect to age, height and
weight. The demographic data are summarized in
Table 1.
Table 1: Patient characteristics (mean ± SD).
Placebo 300 mg 600 mg 1200 mg
n = 64 n = 62 n = 62 n = 64
Age (years) 35.5± 9.9 37.4± 10.3 36.3± 10.7 38.2± 10.7
Height (cm) 171.9± 10.0 170.9± 9.4 172.1± 10.6 171.9± 11.3
Weight (kg) 76.1± 15.3 73.2± 13.2 79.4± 15.6 75.1± 14.2
Sex (M :F) 44 : 20 37 : 25 44 : 18 37 : 27
The majority of patients (59%) were taking two
AEDs at entry to the study. Details of patients’ AED
medication at entry are shown in Table 2. Overall, the
most frequently taken AEDs were: CBZ, PHT, sodium
valproate, lamotrigine and vigabatrin.
Table 2: Number of antiepileptic drugs taken by each patient
at entry to the study.
Number of Placebo 300 mg 600 mg 1200 mg
AEDs n = 64 n = 62 n = 62 n = 64
1 9 8 14 9
2 41 41 28 39
3 12 11 18 16
4 2 1 2 0
5 0 1 0 0
Table 3 shows the duration of epilepsy was similar
in each treatment group (between 23 and 25 years) and
aetiology was most frequently recorded as idiopathic.
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Table 3: Duration (mean ± SD) and aetiology of epilepsy.
Placebo 300 mg 600 mg 1200 mg
n = 64 n = 62 n = 62 n = 64
Duration (years) 23± 11 25± 12 23± 11 24± 12
Aetiology
Idiopathic 31 32 33 40
Head injury 5 11 11 5
Birth trauma 5 7 7 4
Cerebral infection 6 3 5 6
Congenital
abnormality 4 2 2 3
Other 13 7 4 6
In all four treatment groups, complex partial
seizures were the most common seizure. Only two
patients had seizures that were unclassified. Many
patients recorded more than one type of seizure.
Table 4 summarizes the classification of seizures for
patients by treatment group.
Table 4: Seizure classification.
Type of Seizurea Placebo 300 mg 600 mg 1200 mg
n = 64 n = 62 n = 62 n = 64
Simple partial 21 24 20 24
Complex partial 54 49 49 51
Secondary generalized 38 44 48 41
Primary generalized 7 5 5 6
Unclassified 1 0 1 0
a Some patients had more than one type of seizure.
Disposition of patients
A total of 252 patients were randomized and received
study treatment, at 23 centres, with 215 completing
the double-blind continuation period. The number
of patients recruited at each centre ranged from 1
to 36. The numbers of patients at each stage of
the study are shown in Fig. 2. Patient withdrawals
during the double-blind treatment period are shown
in Table 5. There were more withdrawals due to
adverse events in the 600 and 1200 mg/day groups
than in the 300 mg/day and placebo groups during
the double-blind period. All 252 patients who received
treatment were included in the safety analysis. A
total of 219 patients completed at least 14 days
of treatment following the titration phase and were
included in the efficacy analyses; four of these
patients withdrew before completing the double-blind
continuation period.
Table 5: Number of patients withdrawn during the
double-blind treatment period.
Reasona Placebo 300 mg 600 mg 1200 mg
n = 64 n = 62 n = 62 n = 64
Adverse event 5 (8%) 5 (8%) 13 (21%) 13 (20%)
Death 0 0 3 1
Worsening epilepsy 0 1 4 3
Other adverse event 5 5 7 11
No improvement in symptoms 2 (3%) 1 (2%) 1 (2%) 2 (3%)
Withdrew consent 1 (2%) 1 (2%) 0 0
Total 6 (9%) 5 (8%) 13 (21%) 13 (20%)
a Patients may have more than one reason for withdrawal.
Efficacy results
Responder rate
The results for the primary efficacy variable are
presented in Table 6 and illustrated in Fig. 3. The
responder rate was 7% (4/58) of the patients in
the placebo group and 23% (12/52) of the patients
in the remacemide hydrochloride 1200 mg/day
group. A statistically significant difference among the
treatments was observed overall (P = 0.038), and a
pairwise comparison between remacemide hydrochlo-
ride 1200 mg/day and placebo was significant and
in favour of remacemide hydrochloride 1200 mg/day
(P = 0.016). No patients became seizure-free during
the study.
Table 6: Percentage of patients with a reduction from
baseline in monthly seizure frequency of at least 50%.
Treatment group Placebo 300 mg 600 mg 1200 mg
n = 58 n = 58 n = 51 n = 52
% patients 7 9 10 23
(95% CI) (0–13) (1–16) (2–18) (12–35)
P value = 0.038.
In a subsequent analysis, the proportion of patients
whose seizure frequencies increased by at least 100%
was found to be 2% in the placebo group and for
remacemide hydrochloride: 3% in the 300 mg/day
group, 4% in the 600 mg/day group and 0% in the
1200 mg/day group.
Seizure frequency
Figure 4 shows median monthly seizure frequency
decreased in all groups except the remacemide
hydrochloride 600 mg/day group over the course
of the study. The largest median percentage change
from baseline was in the remacemide hydrochloride
1200 mg/day group (decrease of 15.2%); however,
there was no statistically significant overall treatment
effect (P = 0.214).
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Fig. 2: Number of patients at each stage of the study.
Table 7: Numbers of patients with most frequently occurring adverse events by randomized treatment group.
Adverse event Placebo 300 mg 600 mg 1200 mg
n = 64 n = 62 n = 62 n = 64
Body as a whole:
Fatigue 7 12 12 13
Influenza-like symptoms 2 6 4 3
Physical injury 7 9 6 8
Central and peripheral nervous system:
Convulsions aggravated 5 5 7 6
Dizziness 4 4 8 13
Gait abnormal 0 7 3 12
Headache 14 11 15 19
Gastro-intestinal disorders:
Abdominal pain 10 8 8 4
Diarrhoea 1 6 1 3
Dyspepsia 3 2 9 12
Nausea 5 7 8 16
Vomiting 5 5 6 12
Psychiatric disorders:
Somnolence 5 4 9 9
Respiratory system:
Pharyngitis 1 5 7 3
Upper respiratory tract infection 6 6 12 6
Vision disorders:
Diplopia 1 6 1 9
Vision abnormal 7 3 3 5
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Fig. 3: Differences in responder rates between remacemide and placebo with 95% confidence intervals.
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Fig. 4: Percentage change in median monthly seizure
frequency from baseline, with 95% confidence intervals.
Safety results
Adverse events
The percentage of patients reporting adverse events
during the continuation phase was higher in the
remacemide hydrochloride 600 and 1200 mg/day
groups (72% (39 patients) in each group) than in
the placebo and remacemide hydrochloride 300 mg
groups (47% (27 patients) and 53% (31 patients),
respectively). Most adverse events were mild to
moderate in severity and resolved without treatment
or discontinuation of study drug. The most frequently
occurring adverse event during study treatment was
headache; this occurred to a similar extent in all the
treatment groups. Adverse events that were reported
by more than five patients in any treatment group are
shown in Table 7.
Five patients died during the study (four who
received remacemide hydrochloride and one who was
enrolled but not randomized/treated). None of the
deaths were considered to be related to the study
treatment. For four of the patients, cause of death
was related to epilepsy. The fifth patient (receiving
600 mg/day remacemide hydrochloride) committed
suicide; he had a distant history of possible psychosis
and suicidal/aggressive episodes.
Apart from the deaths, during the double-blind
period, eight patients in the placebo group reported
eight serious events and 12 patients in the three
remacemide hydrochloride treatment groups reported
13 serious events. Four serious adverse events
(all in the remacemide hydrochloride groups) were
considered by the investigator to be possibly related
to treatment; three of these events were reported
for patients receiving 300 mg/day (psychosis, visual
hallucinations and liver function disturbance) and one
was reported for a patient receiving 1200 mg/day
(status epilepticus).
Table 5 shows 36 patients (14%) were withdrawn
from double-blind treatment due to adverse events.
Adverse events leading to withdrawal were mainly
CNS (including increased seizures, headache, dizzi-
ness, ataxia) or gastrointestinal system related.
Other safety assessments
Details of patients who developed laboratory ab-
normalities during the study are summarized in
Table 8. There were no clinically significant trends to
suggest that any of these were related to remacemide
hydrochloride treatment. Similarly, there were no
clinically significant differences between the groups
for changes in ECG parameters or vital signs.
Carbamazepine and phenytoin control
Plasma concentrations of CBZ and PHT were well
controlled during the study7. Table 9 shows the mean
concentrations of both drugs increased slightly follow-
ing administration of remacemide hydrochloride. In
the case of CBZ, the increases were dose-dependent;
however, the mean CBZ change was similar in
responders and non-responders. The proportion of
Table 8: Patients with biochemistry values >100% above the
normal range during treatment.
Placebo 300 mg 600 mg 1200 mg
Gamma GT 33 28 36 31
Alkaline phosphatase 4 0 3 2
SGPT 2 3 3 4
Glucose 2 5 4 5
HDL cholesterol 3 4 1 3
Total cholesterol:HDL cholesterol 0 2 3 2
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Table 9: Summary of mean (±SD) change from baseline in carbamazepine plasma concentration measured during the
continuation period.
Treatment group
Remacemide Hydrochloride (mg/day)
Placebo 300 600 1200
Patients 47 43 40 37
CBZ relative to warning limits
(number of patients)
Above 0 1 2 6
Within 47 42 37 31
Below 0 0 1 0
CBZ concentration differences
(mg/L; double-blind minus baseline)
Mean 0.00 0.32 0.51 0.79
SD 0.73 0.95 0.92 0.89
ta — 1.80 2.80 4.40
P — >0.05 <0.01 <0.001
a Unpaired t-test, relative to placebo difference.
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Fig. 5: Proportion of patients in each treatment group having a carbamazepine dose reduction.
patients who required an adjustment in CBZ dose
increased with increasing dose of remacemide hy-
drochloride. In the placebo group, 4/47 patients (9%)
required an adjustment, compared with 19/44 patients
(43%) in the remacemide hydrochloride 300 mg/day
group, 25/41 (61%) in the 600 mg/day group and
34/39 (87%) in the 1200 mg/day group. Figure 5
shows the extent of dose adjustments was also greater
in the higher dose groups.
There was an apparent overall increase in mean
plasma PHT concentrations with increasing dose
of remacemide hydrochloride; however, there was
wide variation in plasma PHT concentrations in all
treatment groups. There was no correlation between
the percentage reduction in seizure frequency and
plasma concentration of either CBZ or PHT.
Pharmacokinetics of remacemide and the
desglycinyl metabolite
A comparison of mean steady-state plasma concentra-
tions over successive 1-hour time intervals post dose,
demonstrated a reasonable degree of dose proportion-
ality for remacemide, as shown in Fig. 6, and for the
desglycinyl metabolite as shown in Fig. 7. Threshold
plasma concentrations of remacemide and the desg-
lycinyl metabolite for efficacy were not discernable.
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Fig. 6: Mean (+SD) remacemide steady-state plasma concentrations for each 1-hour period over the dosing interval in induced
patients taking remacemide hydrochloride Q.I.D.
0 < = 1 > 1 < = 2 > 2 < = 3 > 3 < = 4 > 4 < = 5 > 5 < = 6
160
140
120
100
80
20
40
60
0
300 mg
600 mg
800 mg
1200 mg
Time period post dose (h)
Pl
as
m
a 
Co
nc
en
tra
tio
n 
(ng
.
m
l−
1 )
Fig. 7: Mean (+SD) desglycinyl metabolite steady-state plasma concentrations for each 1-hour period over the dosing interval in
induced patients taking remacemide hydrochloride Q.I.D.
DISCUSSION
The key efficacy variable, responder rate, showed that
add-on remacemide hydrochloride 1200 mg/day, in a
Q.I.D. regimen, was significantly better than placebo
at halving the number of seizures. The responder rate
of 23% in the remacemide hydrochloride 1200 mg
group was similar to results for other AEDs8.
No patients became seizure-free but this was not
unexpected in such a highly refractory population.
The percentage change in seizure frequency was not
statistically significantly different among the treatment
groups. The greatest median reduction occurred in the
1200 mg/day group (15%), but there was a reduction
of 11% in the placebo group. That the response rates
differed significantly, but not the actual changes in
seizure counts, was unexpected because the latter
measure contains more information and gives a more
powerful test. Subsequent analysis has shown there
was no evidence that the large variation in seizure
frequency was due to worsening of seizures in a
proportion of patients.
Plasma concentrations of CBZ and PHT were
successfully maintained within a target range for
each individual by regular monitoring and dose
adjustments. There was no correlation between the
changes in concentration of either drug and the
reductions in seizures, although the power to detect
such a correlation was weak. Despite the complexity
of the CBZ control procedure, the design proved
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workable. The use of Shewhart control charts enabled
decisions about intervention to be based on individual
probability. The steps taken to preserve the double-
blind were important; without the dummy CBZ dosage
interventions in the placebo-treated patients, the
efficacy of remacemide hydrochloride 1200 mg/day
could have been undermined.
The incidence of adverse events in this study
was what might be expected of the population,
with over half of the patients (56%) reporting
adverse events during baseline, before taking study
medication. The number of adverse events increased
similarly in all groups during dose escalation. The
proportion of patients reporting adverse events during
the continuation phase tended to decrease, which
may suggest development of a degree of tolerance
to adverse events. The adverse event profile of
remacemide hydrochloride was consistent with that
from other studies in a similar patient population.
CNS-related adverse events, such as those seen with
remacemide hydrochloride in this study, are common
to the majority of antiepileptic drugs9.
The incidence of serious adverse events was no
greater in the active treatment groups than in the
placebo group and was no greater during double-blind
treatment than during baseline.
The laboratory, ECG and vital sign measurements
showed no significant changes with remacemide
hydrochloride treatment.
In conclusion, there was an increase in the number
of patients who had a ≥50% reduction in seizure
frequency following treatment with remacemide hy-
drochloride compared with placebo. This reached
statistical significance at 1200 mg/day. In this study,
daily remacemide hydrochloride doses of 300 mg and
600 mg in a Q.I.D. regimen appeared to be sub-
optimal for hepatic enzyme-induced patients.
Remacemide hydrochloride was generally well
tolerated, with few serious adverse events and few
withdrawals due to adverse events. Adverse events
that appeared to distinguish remacemide hydrochlo-
ride from placebo were: fatigue, dizziness, abnor-
mal gait, dyspepsia, nausea, vomiting, somnolence
and diplopia.
There was no obvious relationship between the
plasma concentration of remacemide, or the desg-
lycinyl metabolite, and response to treatment. Plasma
concentrations of remacemide and the desglycinyl
metabolite were broadly proportional to dose.
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